Is Calidi Biotherapeutics, Inc. (CLDI) a Buy, Sell, or Hold?
AMEX : CLDI
Calidi Biotherapeutics, Inc.
$1.63 USD
$0.01 (0.62%)
- Volume
- 159.14K
- Average Volume
- 398.51K
- Market Capitalization
- $750.51K
- P/E Ratio
- -0.02
- Dividend Yield
- 0.00%
- Price Target
- $5.50
- Year High
- $96.94
- Year Low
- $1.49
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.92
Company Overview
AMEX
Eric E. Poma
Biotechnology
Healthcare
CLDI
29
US
USD
Liquidity Metrics
0.46
1.92
1.92
1.73
0.00
Sales & Valuation
-$
0.00
0.21
-0.04
-28.55
Profitability
-$95.2
-$19.91M
0.00%
0.00%
-438.03%
-198.39%
P/E Metrics
-0.02
0.00
0.00
Analyst Price Target & Rating
$5.50
$9.00
$2.00
2/5
2 Analysts
-70.36%
Financial Health Scores
-27.25
1/9
$3.52M
$9.59M
$4.66M
-$18.92M
Key Metrics (TTM)
-$3.63M
0.00
0.21
1.92
-438.03%
-266.77%
-1823.16%
-2466.26%
-727 days
Company Executives
| Name | Title |
|---|---|
| Andrew C. Jackson | Chief Financial Officer & Corporate Secretary |
| Eric E. Poma | Chief Executive Officer & Director |
| Antonio Fernandez Santidrian | Head of Technical Operations & Chief Scientific Officer |
| Guy Travis Clifton | Chief Medical Officer |
Poll Results
No votes yet today — be the first to share your view!
About Calidi Biotherapeutics, Inc. (AMEX:CLDI) Stock
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates ... : NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
2026-07-27 08:00:00
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, presented on July 23, 2026, at the American Association for Cancer Research Drug Discovery and Development (AACR D3) Conference in Boston, MA. The Company presented new data on its CLD-401 program that it expects to enter the clinic in the first quarter of 2027 and its in situ T-cell engager (TCE) program.
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
2026-07-21 08:00:00
SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today recapped 2026 successes to date and provided an update on the Company's upcoming milestones.
2026-07-20 16:30:00
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a biotechnology company pioneering the development of targeted genetic medicine, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-16 (the “Reverse Stock Split”). The Company's common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on July 31, 2026 under the existing symbol of “CLDI.” The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 320703 507.
2026-07-20 16:30:00
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE American: CLDI), a biotechnology company pioneering the development of targeted genetic medicine, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-16 (the "Reverse Stock Split").
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
2026-07-08 16:05:00
SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a biotechnology company pioneering the development of targeted genetic medicine, today announced that in connection with the appointment of Sandra Gurrola as VP Finance, Controller, the Company's Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Ms. Gurrola for the purchase of 100,000 shares with an exercise price of $0.15, which was the closing price of the Company's common stock on July 6, 2026, the date of grant (the “Stock Options”).
2026-06-24 08:00:00
SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, presented data today at the T-cell Engager Therapeutic Summit in San Diego, California. The Company presented data on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically in situ in the tumor microenvironment (“TME”).
2026-06-23 08:00:00
SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 17, 2026.
2026-06-16 08:00:00
IND enabling studies with CLD-401 to continue with IND submission targeted by end of 2026 as Calidi continues to explore regulatory filing for CLD-401 in Australia in parallel IND enabling studies with CLD-401 to continue with IND submission targeted by end of 2026 as Calidi continues to explore regulatory filing for CLD-401 in Australia in parallel
Frequently Asked Questions
-
What is the current Calidi Biotherapeutics, Inc. (CLDI) stock price?
-
Calidi Biotherapeutics, Inc.(AMEX:CLDI) stock price is $1.63 in the last trading session. During the trading session, CLDI stock reached the peak price of $96.944 while $1.488 was the lowest point it dropped to. The percentage change in CLDI stock occurred in the recent session was 0.62% while the dollar amount for the price change in CLDI stock was $0.01.
-
CLDI's industry and sector of operation?
-
The AMEX listed CLDI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CLDI?
-
Andrew C. Jackson | Chief Financial Officer & Corporate Secretary
Eric E. Poma | Chief Executive Officer & Director
Antonio Fernandez Santidrian | Head of Technical Operations & Chief Scientific Officer
Guy Travis Clifton | Chief Medical Officer
| -
How many employees does CLDI have?
-
Number of CLDI employees currently stands at 29. CLDI operates from 4475 Executive Drive, San Diego, CA 92121, US.
-
Link for CLDI official website?
-
Official Website of CLDI is: https://calidibio.com
-
How do I contact CLDI?
-
CLDI could be contacted at phone #858 794 9600 and can also be accessed through its website. CLDI operates from 4475 Executive Drive, San Diego, CA 92121, US.
-
How many shares of CLDI are traded daily?
-
The average number of CLDI shares traded daily for last 3 months was 398.51K.
-
What is the market cap of CLDI currently?
-
The market value of CLDI currently stands at $750.51K with its latest stock price at $1.63